A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

The incidence of HER2 somatic mutations in breast cancer is about 2–4%, mainly occurring in the HR+/HER2- subtype. Preclinical studies suggest that HER2 mutations can lead to constitutive HER2 activation, but effective treatment options for the clinical management of patients with HER2 mutations rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing Ma, Xuelu Li, Qianran Zhang, Ning Li, Siwen Sun, Shanshan Zhao, Zuowei Zhao, Man Li
Formato: Artículo
Lenguaje:English
Publicado: Elsevier 2022-07-01
Colección:Translational Oncology
Materias:
HER2 mutation
Breast cancer
HER2-targeted therapy
Everolimus
Treatment
Acceso en línea:http://www.sciencedirect.com/science/article/pii/S1936523322001036

Internet

http://www.sciencedirect.com/science/article/pii/S1936523322001036

Ejemplares similares